Jaguar Health is a pharmaceuticals company that develops plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal distress, such as chronic, debilitating diarrhea. Co.'s subsidiary, Napo Pharmaceuticals, Inc. (Napo), develops and commercializes proprietary plant-based human pharmaceuticals. Napo's marketed drug Mytesi (crofelemer 125 mg delayed-release tablets) is an oral botanical drug product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Co.'s Canalevia-CA1 (crofelemer delayed-release tablets) drug is an oral plant-based prescription product to treat chemotherapy-induced diarrhea in dogs. The JAGX average annual return since 2015 is shown above.
The Average Annual Return on the JAGX average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether JAGX average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JAGX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|